Clinical trials
Urologic Diseases trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astellas Pharma Europe Ltd. | 3 |
| Astellas Pharma Europe B.V. | 2 |
| Charles University, Czech Republic | 1 |
| European Association of Urology Research Foundation | 1 |
| HI-Bio, A Biogen Company | 1 |
| Institute of Spa and Balneology, public research institution | 1 |
| Medtronic | 1 |
| Novartis Pharmaceuticals | 1 |
| Rainier Therapeutics | 1 |
| Taiho Oncology, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urologic Diseases | 13 |
| Urinary Bladder Diseases | 6 |
| Kidney Diseases | 4 |
| Urinary Bladder, Overactive | 4 |
| Urinary Incontinence | 4 |
| Glomerulonephritis, IGA | 2 |
| Renal Insufficiency | 2 |
| Carcinoma, Renal Cell | 1 |
| Carcinoma, Transitional Cell | 1 |
| Cardiovascular Diseases | 1 |
Trials
Showing 51 to 13 of 13. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.